购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空

Cyclophosphamide hydrate

Rating icon 很棒
产品编号 T0707Cas号 6055-19-2
别名 环磷酰胺一水物, 环磷酰胺水合物, Cyclophosphamide monohydrate

Cyclophosphamide hydrate 是一种 DNA 烷化剂,一种 DNA 合成抑制剂。Cyclophosphamide hydrate 具有抗肿瘤活性、免疫抑制活性等。

Cyclophosphamide hydrate

Cyclophosphamide hydrate

Rating icon 很棒
纯度: 99.65%
产品编号 T0707 别名 环磷酰胺一水物, 环磷酰胺水合物, Cyclophosphamide monohydrateCas号 6055-19-2

Cyclophosphamide hydrate 是一种 DNA 烷化剂,一种 DNA 合成抑制剂。Cyclophosphamide hydrate 具有抗肿瘤活性、免疫抑制活性等。

规格价格库存数量
5 mg¥ 135现货
10 mg¥ 182现货
25 mg¥ 276现货
50 mg¥ 386现货
100 mg¥ 540现货
200 mg¥ 728现货
500 mg¥ 953现货
1 g¥ 1,330现货
大包装 & 定制
加入购物车
实验操作小课堂
查看更多
选择批次:
纯度:≥95%
联系我们获取更多批次信息
TargetMol 的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。

产品介绍

生物活性
产品描述
Cyclophosphamide hydrate is a DNA alkylating agent, an inhibitor of DNA synthesis. Cyclophosphamide hydrate has antitumor and immunosuppressive activities.
体外活性
方法:巨噬细胞 Raw 264.7 用 Cyclophosphamide hydrate (10-250 μg/mL) 处理 48 h,使用 MTT assay 检测细胞活力。
结果:Cyclophosphamide hydrate 对 Raw 264.7 有细胞毒性,IC50 为 145.44 μg/mL。[1]
方法:人乳腺癌细胞 MDA-MB-231 和 MDA-MB-435S 用 Cyclophosphamide hydrate (0.25-1 mM) 处理 4-24 h,使用 Wound healing assay 检测细胞迁移情况。
结果:迁移的 MDA-MB-231 细胞数量的增加取决于 Cyclophosphamide 的浓度,而到 MDA-MB-435S 细胞的迁移显著减少,并且与 Cyclophosphamide 浓度无关。[2]
体内活性
方法:为检测体内抗肿瘤活性,将 Cyclophosphamide hydrate (50-150 mg/kg) 单次腹腔注射给携带小鼠结直肠肿瘤 CT26 的 BALB/c 小鼠。
结果:Cyclophosphamide hydrate 诱导肿瘤体积显著减少。[3]
方法:为检测体内抗肿瘤活性,将 Cyclophosphamide hydrate (140 mg/kg) 口服给药给携带小鼠乳腺癌肿瘤 4T1 的 Balb/c 小鼠,每六天一次,持续十八天。
结果:Cyclophosphamide hydrate 治疗显著抑制了小鼠的肿瘤生长。[4]
激酶实验
9L cells are treated with drug for the times indicated in each experiment. Floating and attached cells are collected, pooled, resuspended in lysis buffer (10 mM HEPES buffer, pH 7.4, containing 2 mM EDTA, 0.1% CHAPS detergent, 5 mM DTT, 350 ng/mL phenylmethylsulfonyl fluoride, 10 ng/mL pepstatin A, 10 ng/mL aprotinin, and 20 ng/mL leupeptin) and lysed by three freeze-thaw cycles (alternating between a dry ice isopropanol bath and a 37°C water bath). Lysates are spun in a bench top centrifuge at full speed for 15 min and the supernatant (cell extract) fraction transferred to a new tube. Cell extracts (20 μL) are assayed for caspase 9, caspase 8, and caspase 3 activity by incubation at 37°C for either 1 h (caspase 3) or 3 h (caspase 9 and caspase 8) in 500 μL of reaction buffer (10 mM HEPES, pH 7.4, 2 mM EDTA, 0.1% CHAPS, and 5 mM DTT) containing 50 μM caspase form-selective substrate: Ac-LETD-AFC for caspase 8; Ac-LEHD-AFC for caspase 9; and Ac-DEVD-AMC for caspase 3. Background activity is determined for each sample as follows. Cell extracts are preincubated for 15 min at room temperature, with or without caspase form-selective inhibitor: 1 μM z-LETD-FMK for caspase 8, 1 μM z-LEHD-FMK for caspase 9, and 5 μL of Casputin for caspase 3. Caspase activity measured in the absence of inhibitor is divided by the background caspase activity measured in the presence of inhibitor. A value of 1 is subtracted from each measured activity, such that a caspase activity of 0 corresponds to no increase in the specific caspase activity with drug treatment. Fluorescence of the caspase product (excitation at 395 nm and emission at 525 nm for AFC substrates, and excitation at 380 nm and emission at 460 nm for the AMC substrate) is measured using a Shimadzu model RF-1501 spectrofluorophotometer and the manufacturer's PC-1501 software package.
细胞实验
9L/pBabe, 9L/Bax, and 9L/Bcl-2 cells are treated with 12, 24, or 50 μM MFA for 72 h. Cells remaining on the plates at 0, 24, 48, and 72 h are washed twice with cold PBS and then stained for 5 min with crystal violet [1.25 g of crystal violet dissolved in a solution containing 50 mL of 37% formaldehyde and 450 mL of methanol]. The stained cells are washed three times in tap water and the plates are allowed to dry. The stain is eluted from the cells with 70% ethanol and the absorbance is then read at 595 nm. The staining intensity of each drug-treated sample (A?595) is then graphed as a percentage of the staining intensity at the 0-h time point.
别名环磷酰胺一水物, 环磷酰胺水合物, Cyclophosphamide monohydrate
化学信息
分子量279.1
分子式C7H17Cl2N2O2P·H2O
CAS No.6055-19-2
SmilesO.ClCCN(CCCl)P1(=O)NCCCO1
密度no data available
储存&溶解度
存储Powder: -20°C for 3 years | Shipping with blue ice.
溶解度信息
DMSO: 50 mg/mL (179.15 mM), The compound is unstable in solution. Please use soon.
H2O: 7 mg/mL (25.08 mM)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
溶液配制表
1mg5mg10mg50mg
1 mM3.5829 mL17.9147 mL35.8295 mL179.1473 mL
5 mM0.7166 mL3.5829 mL7.1659 mL35.8295 mL
10 mM0.3583 mL1.7915 mL3.5829 mL17.9147 mL
20 mM0.1791 mL0.8957 mL1.7915 mL8.9574 mL
1mg5mg10mg50mg
50 mM0.0717 mL0.3583 mL0.7166 mL3.5829 mL
100 mM0.0358 mL0.1791 mL0.3583 mL1.7915 mL

计算器

  • 摩尔浓度 计算器
  • 稀释 计算器
  • 配液 计算器
  • 分子量 计算器

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
TargetMol | Animal experiments比如您的给药剂量是 10 mg/kg ,每只动物体重 20 g ,给药体积 100 μLTargetMol | Animal experiments 一共给药动物 10 只 ,您使用的配方为 5% TargetMol | reagent DMSO+ 30%PEG300+ 5%Tween 80 + 60% ddH2O. 那么您的工作液浓度为 2 mg/mL
母液配置方法: 2 mg 药物溶于 50 μLDMSOTargetMol | reagent ( 母液浓度为 40 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:50μLDMSOTargetMol | reagent 母液,添加 300 μLPEG300TargetMol | reagent 混匀澄清,再加 50μLTween 80, 混匀澄清,再加 600μLddH2OTargetMol | reagent 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

1 请输入动物实验的基本信息
mg/kg
g
μL
2 请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
%Tween 80
%ddH2O

剂量转换

对于不同动物的给药剂量换算,您也可以参考 更多

关键词

评论列表

4个月前
5.0
Rating icon 很棒

评论内容

Related Tags: buy Cyclophosphamide hydrate | purchase Cyclophosphamide hydrate | Cyclophosphamide hydrate cost | order Cyclophosphamide hydrate | Cyclophosphamide hydrate chemical structure | Cyclophosphamide hydrate in vivo | Cyclophosphamide hydrate in vitro | Cyclophosphamide hydrate formula | Cyclophosphamide hydrate molecular weight